Compare STWD & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STWD | MMED |
|---|---|---|
| Founded | 2009 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.1B |
| IPO Year | 2009 | 2025 |
| Metric | STWD | MMED |
|---|---|---|
| Price | $12.59 | $18.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 16 |
| Target Price | $18.88 | ★ $25.47 |
| AVG Volume (30 Days) | 5.8M | ★ 15.5M |
| Earning Date | 11-06-2026 | 11-13-2026 |
| Dividend Yield | ★ 15.23% | N/A |
| EPS Growth | ★ 4.55 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | $1,844,289,000.00 | ★ $3,102,000,000.00 |
| Revenue This Year | $287.08 | $10.76 |
| Revenue Next Year | $9.52 | $8.51 |
| P/E Ratio | $84.10 | ★ N/A |
| Revenue Growth | N/A | ★ 14.25 |
| 52 Week Low | $11.84 | $10.65 |
| 52 Week High | $18.66 | $24.43 |
| Indicator | STWD | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 48.76 |
| Support Level | $11.84 | $16.55 |
| Resistance Level | $12.83 | $20.88 |
| Average True Range (ATR) | 0.35 | 0.80 |
| MACD | 0.11 | 0.16 |
| Stochastic Oscillator | 52.80 | 75.42 |
Starwood Property Trust Inc is a real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans, commercial mortgage-backed securities, and other real estate investments in the U.S., Australia, and Europe. The company has four reportable business segments: Commercial and Residential Lending, Infrastructure Lending, Property, and Investing and Servicing. The majority of its revenue is generated from the Commercial and Residential Lending segment, which engages mainly in originating, acquiring, financing, and managing commercial first mortgages, non-agency residential mortgages (residential loans), commercial mortgage-backed securities (CMBS), residential mortgage-backed securities (RMBS), and other real estate and related debt investments.
While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy. Medtronic acquired MiniMed in 2001 and then spun it out in 2026 (though Medtronic still owns roughly 90% of MiniMed shares, which will be relayed to its shareholders as a tax-free distribution in the foreseeable future). MiniMed is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables.